Remoxy slated for mid-2010 resubmission

Needing time to gather data on the stability of their experimental pain med Remoxy, King Pharmaceuticals and Pain Therapeutics say they may have to wait until mid-2010 to resubmit their marketing application. The FDA snubbed the developers in December. Shares for both companies slid on the news of the delay. Release l Report